389 related articles for article (PubMed ID: 15124203)
21. Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors.
Li C; Nair L; Liu T; Li F; Pichardo J; Agrawal S; Chase R; Tong X; Uss AS; Bogen S; Njoroge FG; Morrison RA; Cheng KC
Biochem Pharmacol; 2008 Mar; 75(5):1186-97. PubMed ID: 18164692
[TBL] [Abstract][Full Text] [Related]
22. The rise of PAMPA.
Avdeef A
Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):325-42. PubMed ID: 16922646
[TBL] [Abstract][Full Text] [Related]
23. Caco-2 cell permeability assays to measure drug absorption.
van Breemen RB; Li Y
Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):175-85. PubMed ID: 16922635
[TBL] [Abstract][Full Text] [Related]
24. New biomimetic barrier Permeapad™ for efficient investigation of passive permeability of drugs.
di Cagno M; Bibi HA; Bauer-Brandl A
Eur J Pharm Sci; 2015 Jun; 73():29-34. PubMed ID: 25840123
[TBL] [Abstract][Full Text] [Related]
25. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model.
Kapitza SB; Michel BR; van Hoogevest P; Leigh ML; Imanidis G
Eur J Pharm Biopharm; 2007 Apr; 66(1):146-58. PubMed ID: 17071065
[TBL] [Abstract][Full Text] [Related]
26. Clearance-dependent underprediction of in vivo intrinsic clearance from human hepatocytes: comparison with permeabilities from artificial membrane (PAMPA) assay, in silico and caco-2 assay, for 65 drugs.
Hallifax D; Turlizzi E; Zanelli U; Houston JB
Eur J Pharm Sci; 2012 Apr; 45(5):570-4. PubMed ID: 22214813
[TBL] [Abstract][Full Text] [Related]
27. Permeation characteristics of a hydrophilic basic compound across a bio-mimetic artificial membrane.
Sugano K; Nabuchi Y; Machida M; Asoh Y
Int J Pharm; 2004 May; 275(1-2):271-8. PubMed ID: 15081157
[TBL] [Abstract][Full Text] [Related]
28. The impact of protein on Caco-2 permeability of low mass balance compounds for absorption projection and efflux substrate identification.
Liu T; Chang LJ; Uss A; Chu I; Morrison RA; Wang L; Prelusky D; Cheng KC; Li C
J Pharm Biomed Anal; 2010 Apr; 51(5):1069-77. PubMed ID: 20036089
[TBL] [Abstract][Full Text] [Related]
29. Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion.
Flaten GE; Dhanikula AB; Luthman K; Brandl M
Eur J Pharm Sci; 2006 Jan; 27(1):80-90. PubMed ID: 16246536
[TBL] [Abstract][Full Text] [Related]
30. Predicting both passive intestinal absorption and the dissociation constant toward albumin using the PAMPA technique.
Bujard A; Sol M; Carrupt PA; Martel S
Eur J Pharm Sci; 2014 Oct; 63():36-44. PubMed ID: 25008117
[TBL] [Abstract][Full Text] [Related]
31. PAMPA--a drug absorption in vitro model 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates.
Avdeef A; Nielsen PE; Tsinman O
Eur J Pharm Sci; 2004 Aug; 22(5):365-74. PubMed ID: 15265506
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of cocktail approach to standardise Caco-2 permeability experiments.
Koljonen M; Hakala KS; Ahtola-Sätilä T; Laitinen L; Kostiainen R; Kotiaho T; Kaukonen AM; Hirvonen J
Eur J Pharm Biopharm; 2006 Nov; 64(3):379-87. PubMed ID: 16914297
[TBL] [Abstract][Full Text] [Related]
33. A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Int J Pharm; 2016 Mar; 501(1-2):102-11. PubMed ID: 26836708
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of in vitro brain penetration: optimized PAMPA and MDCKII-MDR1 assay comparison.
Carrara S; Reali V; Misiano P; Dondio G; Bigogno C
Int J Pharm; 2007 Dec; 345(1-2):125-33. PubMed ID: 17624703
[TBL] [Abstract][Full Text] [Related]
35. Prediction of blood-brain barrier permeation of α-adrenergic and imidazoline receptor ligands using PAMPA technique and quantitative-structure permeability relationship analysis.
Vucicevic J; Nikolic K; Dobričić V; Agbaba D
Eur J Pharm Sci; 2015 Feb; 68():94-105. PubMed ID: 25542610
[TBL] [Abstract][Full Text] [Related]
36. Drug permeability profiling using cell-free permeation tools: Overview and applications.
Berben P; Bauer-Brandl A; Brandl M; Faller B; Flaten GE; Jacobsen AC; Brouwers J; Augustijns P
Eur J Pharm Sci; 2018 Jul; 119():219-233. PubMed ID: 29660464
[TBL] [Abstract][Full Text] [Related]
37. [Advances in parallel artificial membrane permeability assay and its applications].
Wu YF; Liu H; Ni JM
Yao Xue Xue Bao; 2011 Aug; 46(8):890-5. PubMed ID: 22007511
[TBL] [Abstract][Full Text] [Related]
38. QSAR application for the prediction of compound permeability with in silico descriptors in practical use.
Nakao K; Fujikawa M; Shimizu R; Akamatsu M
J Comput Aided Mol Des; 2009 May; 23(5):309-19. PubMed ID: 19241121
[TBL] [Abstract][Full Text] [Related]
39. A novel screening strategy to identify ABCB1 substrates and inhibitors.
von Richter O; Glavinas H; Krajcsi P; Liehner S; Siewert B; Zech K
Naunyn Schmiedebergs Arch Pharmacol; 2009 Jan; 379(1):11-26. PubMed ID: 18758752
[TBL] [Abstract][Full Text] [Related]
40. Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans.
Saitoh R; Sugano K; Takata N; Tachibana T; Higashida A; Nabuchi Y; Aso Y
Pharm Res; 2004 May; 21(5):749-55. PubMed ID: 15180329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
